EHA 2026: Germline Testing Beyond Family History in AML and MDS

At the EHA Congress 2026, Panagiotis Baliakas, Senior Lecturer/Associate Professor, Department of Immunology, Genetics and Pathology, Uppsala University, Sweden, presents results from a prospective study of germline predisposition in myeloid neoplasia. He discusses findings suggesting that young patients with AML or MDS may benefit from germline investigation regardless of family history, supporting age at diagnosis as a key criterion for genetic testing.